ERK Inhibitor Solid Dispersion for Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for ERK1/2 inhibitor compositions that are stable, easy to formulate, and have improved bioavailability and pharmacokinetic profiles to enhance therapeutic efficacy, particularly in cancer treatment.
Innovation Solution
The development of pharmaceutical compositions comprising Compound I, a specific ERK1/2 inhibitor, in the form of a solid dispersion molecularly dispersed within a polymer matrix of hydroxypropylmethyl cellulose acetate succinate (HPMCAS), which improves bioavailability and stability, and is administered as a tablet or solution with a specific ratio of Compound I to HPMCAS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If Compound I is formulated as a conventional pharmaceutical composition, then the formulation process is simple, but the bioavailability and pharmacokinetic profiles are insufficient
Solution Approach 1:
The patent changes the physical and chemical parameters of Compound I by converting it from crystalline form to amorphous form through solid dispersion technology. This parameter change increases the surface area and solubility of the compound, thereby improving bioavailability and pharmacokinetic profiles while maintaining formulation feasibility
Solution Approach 2:
The patent creates a composite material system by dispersing Compound I within a polymer matrix (such as HPMC or HPMCAS). This composite structure combines the therapeutic properties of Compound I with the stabilizing and solubilizing properties of the polymer, achieving both improved bioavailability and ease of manufacture
2Stability of the object's composition
If Compound I is formulated with stabilizing agents and excipients, then the stability is improved, but the formulation complexity increases
Solution Approach 1:
The patent uses a polymer matrix as an intermediary substance that stabilizes Compound I without requiring multiple separate stabilizing agents. The polymer acts as a mediator that protects the compound from degradation while maintaining a relatively simple formulation structure, thus improving stability without proportionally increasing complexity
3Reliability
If the dosage form is administered as a solid dispersion, then the bioavailability is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent performs preliminary actions by pre-mixing Compound I with the polymer matrix under controlled conditions to ensure uniform amorphous dispersion before final formulation steps. This preliminary dispersion action reduces the need for high precision during subsequent manufacturing steps, achieving both improved bioavailability and manageable manufacturing requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions demonstrate improved bioavailability and pharmacokinetic profiles, as evidenced by enhanced plasma concentrations and area under the curve (AUC) in animal studies, indicating increased therapeutic potential for cancer treatment.
Implementation Method 1
Compound I, or a pharmaceutically acceptable salt or solvate thereof, is molecularly dispersed within a polymer matrix comprising hydroxypropylmethyl cellulose acetate succinate (HPMCAS)
Data Source
AI summary
The present disclosure relates generally to compositions comprising Compound (I).